An official website of the United States government

PubChem

Tarenflurbil

PubChem CID
92337
Structure
Tarenflurbil_small.png
Tarenflurbil_3D_Structure.png
Molecular Formula
Synonyms
  • Tarenflurbil
  • 51543-40-9
  • (R)-Flurbiprofen
  • Flurizan
  • R-Flurbiprofen
Molecular Weight
244.26 g/mol
Computed by PubChem 2.2 (PubChem release 2025.09.15)
Dates
  • Create:
    2005-06-08
  • Modify:
    2026-04-04
Description
(R)-flurbiprofen is a flurbiprofen. It is an enantiomer of a (S)-flurbiprofen.
Tarenflurbil is an investigational drug that was studied in patients with mild Alzheimer's disease. It is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid beta 42 (Aβ42) in cultured human cells and in animal models. Aβ42 is the primary initiator of neurotoxicity and amyloid plaque development in the brains of Alzheimer's disease patients. In June 2008 development of the drug for Alzheimer's disease was discontinued. Tarenflurbil has also been used in trials studying the treatment of Prostate Cancer.
Tarenflurbil is an orally active synthetic enantiomer of flurbiprofen. Tarenflurbil activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. R-flurbiprofen does not inhibit the enzyme cyclo-oxygenase.
See also: Propionic Acid (annotation moved to); Flurbiprofen (annotation moved to).

1 Structures

1.1 2D Structure

Chemical Structure Depiction
Tarenflurbil.png

1.2 3D Conformer

Interactive Chemical Structure Model
Conformer of 10

2 Names and Identifiers

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid
Computed by Lexichem TK 2.9.3 (PubChem release 2025.09.15)

2.1.2 InChI

InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m1/s1
Computed by InChI 1.07.4 (PubChem release 2025.09.15)

2.1.3 InChIKey

SYTBZMRGLBWNTM-SNVBAGLBSA-N
Computed by InChI 1.07.4 (PubChem release 2025.09.15)

2.1.4 SMILES

C[C@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
Computed by OEChem 4.2.0 (PubChem release 2025.09.15)

2.2 Molecular Formula

C15H13FO2
Computed by PubChem 2.2 (PubChem release 2025.09.15)

2.3 Other Identifiers

2.3.1 CAS

2.3.2 European Community (EC) Number

2.3.3 UNII

2.3.4 AIDS Number

2.3.5 ChEBI ID

2.3.6 ChEMBL ID

2.3.7 DrugBank ID

2.3.8 DSSTox Substance ID

2.3.9 International Nonproprietary Names (INN)

TARENFLURBIL

2.3.10 KEGG ID

2.3.11 Metabolomics Workbench ID

2.3.12 NCI Thesaurus Code

2.3.13 Nikkaji Number

2.3.14 NSC Number

2.3.15 United States Adopted Name (USAN)

2.3.16 Wikidata

2.3.17 Wikipedia

2.4 Synonyms

2.4.1 MeSH Entry Terms

MeSH Entry Terms for tarenflurbil
tarenflurbil
MeSH Entry Terms for flurizan
flurizan
MeSH Entry Terms for MPC-7869
  • MPC-7869
  • MPC7869
MeSH Entry Terms for E-7869
E-7869

2.4.2 Depositor-Supplied Synonyms

3 Chemical and Physical Properties

3.1 Computed Properties

Property Name
Molecular Weight
Property Value
244.26 g/mol
Reference
Computed by PubChem 2.2 (PubChem release 2025.09.15)
Property Name
XLogP3
Property Value
4.2
Reference
Computed by XLogP3 3.0 (PubChem release 2025.09.15)
Property Name
Hydrogen Bond Donor Count
Property Value
1
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Hydrogen Bond Acceptor Count
Property Value
3
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Rotatable Bond Count
Property Value
3
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Exact Mass
Property Value
244.08995782 Da
Reference
Computed by PubChem 2.2 (PubChem release 2025.09.15)
Property Name
Monoisotopic Mass
Property Value
244.08995782 Da
Reference
Computed by PubChem 2.2 (PubChem release 2025.09.15)
Property Name
Topological Polar Surface Area
Property Value
37.3 Ų
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Heavy Atom Count
Property Value
18
Reference
Computed by PubChem
Property Name
Formal Charge
Property Value
0
Reference
Computed by PubChem
Property Name
Complexity
Property Value
286
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Isotope Atom Count
Property Value
0
Reference
Computed by PubChem
Property Name
Defined Atom Stereocenter Count
Property Value
1
Reference
Computed by PubChem
Property Name
Undefined Atom Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Defined Bond Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Undefined Bond Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Covalently-Bonded Unit Count
Property Value
1
Reference
Computed by PubChem
Property Name
Compound Is Canonicalized
Property Value
Yes
Reference
Computed by PubChem (release 2025.09.15)

3.2 Chemical Classes

Biphenyls

3.2.1 Drugs

Pharmaceuticals -> Listed in ZINC15
S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749

4 Spectral Information

4.1 Mass Spectrometry

4.1.1 LC-MS

MS Category
Experimental
MS Type
LC-MS
MS Level
MS2
Precursor Type
[M+H]+
Precursor m/z
245.097
Instrument
qTof
Ionization Mode
positive
Top 5 Peaks

199.090988 100

178.075974 57.16

179.084442 30.64

184.065948 23.25

183.060608 16.01

Thumbnail
Thumbnail

6 Chemical Vendors

50 vendors
PubChem SID: 374252398
Purchasable Chemical: AS-44113
PubChem SID: 523541249
Purchasable Chemical: X217859
PubChem SID: 438493820
Purchasable Chemical: S548950
CATO Research Chemicals Inc. (Chemical Vendors, Research and Development)
PubChem SID: 513775003
Purchasable Chemical: C4X-144430
PubChem SID: 472461401
Purchasable Chemical: R227922
PubChem SID: 490660593
Purchasable Chemical: 519561
PubChem SID: 319884972
Purchasable Chemical: CS-6056
PubChem SID: 521252955
Purchasable Chemical: API51543409
PubChem SID: 521252956
Purchasable Chemical: API51543409-1
PubChem SID: 522870398
Purchasable Chemical: RM-F210646
PubChem SID: 434700898
Purchasable Chemical: CSSB00016999465
PubChem SID: 508734861
Purchasable Chemical: MSK8083
PubChem SID: 518804172
Purchasable Chemical: MSK8083-100A
PubChem SID: 485280332
Purchasable Chemical: TRC-F598730
PubChem SID: 496034419
Purchasable Chemical: TRC-F598730-1G
PubChem SID: 496034421
Purchasable Chemical: TRC-F598730-250MG
PubChem SID: 521752554
Purchasable Chemical: AG003C3U
PubChem SID: 491982842
Purchasable Chemical: MCULE-3439710050
PubChem SID: 492840180
Purchasable Chemical: MCULE-4717843338
PubChem SID: 254761129
Purchasable Chemical: 51543-40-9
PubChem SID: 488317266
Purchasable Chemical: NP3244
PubChem SID: 381970857
Purchasable Chemical: AA003C12
PubChem SID: 463756838
Purchasable Chemical: LQ5201
PubChem SID: 91699354
Purchasable Chemical: MolPort-003-936-370
PubChem SID: 472956366
Purchasable Chemical: sc-205487
PubChem SID: 523956452
Purchasable Chemical: 51543-40-9
PubChem SID: 470634392
Purchasable Chemical: CQ_51543-40-9
PubChem SID: 523091754
Purchasable Chemical: Y4279841
PubChem SID: 491529193
Purchasable Chemical: TX003D9I
PubChem SID: 322079938
Purchasable Chemical: PI-21767
PubChem SID: 381233176
Purchasable Chemical: A841572
PubChem SID: 514060697
Purchasable Chemical: 226495
PubChem SID: 500211453
Purchasable Chemical: V7565
PubChem SID: 458714771
Purchasable Chemical: 96994
PubChem SID: 464560861
Purchasable Chemical: starbld0819013
PubChem SID: 375333006
Purchasable Chemical: BD21151
PubChem SID: 355036789
Purchasable Chemical: I003858
PubChem SID: 438650704
Purchasable Chemical: ACM51543409
PubChem SID: 152030647
Purchasable Chemical: AKOS015891228
PubChem SID: 319884171
Purchasable Chemical: HY-10291
PubChem SID: 446363423
Purchasable Chemical: B1684577
PubChem SID: 506207541
Purchasable Chemical: CAS-51543-40-9
PubChem SID: 319547126
Purchasable Chemical: 245811
PubChem SID: 468855755
Purchasable Chemical: JH319215
PubChem SID: 516449655
Purchasable Chemical: orb1689861
PubChem SID: 488186703
Purchasable Chemical: F275360
PubChem SID: 508428042
Purchasable Chemical: ACONCH945
PubChem SID: 405416525
Purchasable Chemical: DC24159
PubChem SID: 507593873
Purchasable Chemical: EC003E9M
PubChem SID: 444129274
Purchasable Chemical: AB55458
PubChem SID: 503329022
Purchasable Chemical: AJ55458
PubChem SID: 443842745
Purchasable Chemical: T5843
PubChem SID: 251917415
Purchasable Chemical: 2619
PubChem SID: 251916067
Purchasable Chemical: 51543-40-9
PubChem SID: 402339447
Purchasable Chemical: AB542762
PubChem SID: 440035645
Purchasable Chemical: DY557846
PubChem SID: 24878847
Purchasable Chemical: 545740_ALDRICH

7 Drug and Medication Information

7.1 Drug Indication

3 items
MeSH Heading
EFO Term
Max Phase
Phase 3
MeSH Heading
EFO Term
Max Phase
Phase 3
Investigated for use/treatment in alzheimer's disease and prostate cancer.

7.2 Clinical Trials

7.2.1 ClinicalTrials.gov

6 items
  • TMP001 in Relapsing-remitting Multiple Sclerosis
    Phase: Phase 2
    Status: Completed
    Date: 2018-11-21
  • Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy Subjects
    Phase: Phase 1
    Status: Completed
    Date: 2015-09-11
  • R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence
    Phase: Phase 2
    Status: Unknown status
    Date: 2013-12-18
  • Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
    Phase: Phase 3
    Status: Completed
    Date: 2009-05-05
  • Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
    Phase: Phase 3
    Status: Terminated
    Date: 2008-08-05
Page of 2

7.2.2 EU Clinical Trials Register

4 items
  • TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial
    Phase: Phase 2
    Status: Completed
    Date: 2015-07-16
  • Phase IIa, multi-center, randomized, double-blind, vehicle-controlled study for assessment of clinical skin condition and effects on barrier impairment of a topical formulation containing tarenflurbil on lesional skin in subjects with mild to moderate atopic eczema
    Phase: Phase 2
    Status: Completed
    Date: 2011-11-29
  • Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with
    Phase: Phase 3
    Status: Completed, Prematurely Ended, Ongoing
    Date: 2008-01-04
  • Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's Type
    Phase: Phase 3
    Status: Completed, Prematurely Ended
    Date: 2006-07-31

7.3 Drug Development Summary

Max Phase
Phase 3

7.4 Drug Targets

6 items
Structure
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Gamma-secretase modulator
Structure
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Gamma-secretase modulator
Structure
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Gamma-secretase modulator
Structure
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Gamma-secretase modulator
Structure
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Gamma-secretase modulator
Page of 2

8 Pharmacology and Biochemistry

8.1 MeSH Pharmacological Classification

Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS.
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Gamma Secretase Inhibitors and Modulators
Agents that suppress GAMMA-SECRETASE by inhibiting or modulating its activities. Targeted enzymatic activities include its involvement in accumulation of toxic AMYLOID BETA-PEPTIDES (e.g., Aβ42) in ALZHEIMER DISEASE and activation of NOTCH RECEPTOR mediated SIGNAL PATHWAYS in certain cancer types.
Cyclooxygenase Inhibitors
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

8.2 Metabolism / Metabolites

Flurbiprofen has known human metabolites that include (2S,3S,4S,5R)-6-[(2R)-2-(3-fluoro-4-phenylphenyl)propanoyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560

8.3 Mechanism of Action

MPC-7869 is not an inhibitor of cyclooxygenase enzymes (COX-1 and COX-2). The compound modulates the signal transduction and transcription activation pathways associated with nuclear factor kappaB (NFkappaB), a principle transcription factor in the expression of many molecules involved in cell growth, cell death and inflammation. In addition, MPC-7869 has recently been shown to modulate gamma-secretase and selectively lower levels of Abeta42 peptide in vitro and in vivo, and to reduce amyloid pathology in the brain. MPC-7869 has an excellent safety profile and is very potent in animal models of cancer and Alzheimer's disease. In transgenic mouse studies, MPC-7869 reduced brain amyloid levels and prevented memory loss.

8.4 Transformations

1 item

9 Safety and Hazards

9.1 Hazards Identification

9.1.1 GHS Classification

Pictogram(s)
Acute Toxic
Signal
Danger
GHS Hazard Statements
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
Precautionary Statement Codes
ECHA C&L Notifications Summary

Aggregated GHS information provided per 68 reports by companies from 3 notifications to the ECHA C&L Inventory.

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

9.1.2 Hazard Classes and Categories

Acute Tox. 3 (100%)

10 Literature

10.1 Consolidated References

454 items
Page of 91

10.2 Springer Nature References

295 items
Page of 59
43 items
Page of 9

10.3 Thieme References

4 items

10.4 Chemical Co-Occurrences in Literature

Chemical
Selected evidence
84 articles
View All
Chemical
Selected evidence
100 articles
View All

10.5 Chemical-Gene Co-Occurrences in Literature

Gene/Protein/Enzyme
Selected evidence
10 articles
View All
Gene/Protein/Enzyme
Selected evidence
3 articles
View All

10.6 Chemical-Disease Co-Occurrences in Literature

Disease
Selected evidence
10 articles
View All
Disease
Selected evidence
3 articles
View All
Disease
Selected evidence
1 article
View All

10.7 Chemical-Organism Co-Occurrences in Literature

Organism
Selected evidence
20 articles
View All
Organism
Selected evidence
7 articles
View All

11 Patents

11.1 Depositor-Supplied Patent Identifiers

14,620 items
Page of 2,924

11.2 WIPO PATENTSCOPE

11.3 Chemical Co-Occurrences in Patents

Chemical
Selected evidence
47 patents from 43 patent families
View All

11.4 Chemical-Disease Co-Occurrences in Patents

11.5 Chemical-Gene Co-Occurrences in Patents

Gene
Selected evidence
133 patents from 104 patent families
View All
Gene
Selected evidence
28 patents from 23 patent families
View All

11.6 Chemical-Organism Co-Occurrences in Patents

Organism
Selected evidence
101 patents from 83 patent families
View All
Organism
Selected evidence
Organism
Selected evidence
241 patents from 161 patent families
View All

12 Interactions and Pathways

12.1 Protein Bound 3D Structures

3 items
  • Structure image
    X-ray structure of high-strength hydrogel-grown FABP3 crystal soaked in 50% DMSO solution containing Flurbiprofen
    PDB Code: 7EUV
    Resolution: 1.280000 Å
  • Structure image
    AKR1C3 complex with flurbiprofen
    PDB Code: 3R94
    Resolution: 2.013000 Å
    Evidence PMID: 22937138
  • Structure image
    Structure of (R)-flurbiprofen bound to mCOX-2
    PDB Code: 3RR3
    Resolution: 2.842000 Å
    Evidence PMID: 22053353

12.1.1 Ligands from Protein Bound 3D Structures

PDBe Ligand Code
PDBe Structure Code
PDBe Conformer
Interactive Chemical Structure Model

12.2 Chemical-Target Interactions

21 items
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Modulator
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Modulator
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Inhibitor
Evidence
Data Source
Page of 5

13 Biological Test Results

13.1 BioAssay Results

431 items
Page of 87

14 Classification

14.1 MeSH Tree


  • MeSH Concept: M0491929
    MeSH Descriptor: C505522
  • R-enantiomer of flurbiprofen but not a COX inhibitor; modulates NF-kB, gamma-secretase, amyloid beta-protein;
    MeSH Concept: M0542305
    MeSH Descriptor: C505522

  • MeSH Concept: M0514536
    MeSH Descriptor: D005480

  • MeSH Concept: M0491928
    MeSH Descriptor: C505522

14.2 NCI Thesaurus Tree

  • An orally active synthetic enantiomer of flurbiprofen. Tarenflurbil activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. R-flurbiprofen does not inhibit the enzyme cyclo-oxygenase.

14.3 ChEBI Ontology

14.4 KEGG: Target-based Classification of Drugs

14.5 ChemIDplus

  • CTD
    Comparative Toxicogenomics Database - CTD selects and organizes gene, sequence, chemical, reference, and taxonomic data about gene-chemical interactions. It is hosted at North Carolina State University (NCSU).
  • ChEBI
    Chemical Entities of Biological Interest - Dictionary of molecular entities focused on "small" chemical compounds. ChEBI is part of the EMBL-European Bioinformatics Institute.
  • ClinicalTrials.gov
    ClinicalTrials.gov - ClinicalTrials.gov offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and conditions
  • DSL
    Domestic Substance List of Canada - The DSL list is an inventory of substances manufactured in, imported into or used in Canada on a commercial scale
  • DrugPortal
    Drug Information Portal - Portal to selected drug information from the U.S. National Library of Medicine and other key U.S. Government agencies
Page of 4

14.6 ChEMBL Target Tree

  • Enzyme
    Biological molecules that possess catalytic activity. They may occur naturally or be synthetically created. Enzymes are usually proteins, however CATALYTIC RNA and CATALYTIC DNA molecules have also been identified. [MESH:D004798]
  • Oxidoreductase
    The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) [MESH:D010088]
  • Membrane receptor
    Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. [MESH:D011956]
  • Aspartic protease A22A regulatory subfamily
  • CXC chemokine receptor
    Chemokine receptors that are specific for CXC CHEMOKINES. [MESH:D054387]
Page of 2

14.7 UN GHS Classification

  • H301: Toxic if swallowed [Danger: Acute toxicity, oral]
  • Acute toxicity, oral
  • GHS06: Acute Toxicity GHS06
  • P264: Wash hands [and ...] thoroughly after handling.
  • P270: Do not eat, drink or smoke when using this product.
Page of 2

14.8 NORMAN Suspect List Exchange Classification

  • A 2017 list of REACH chemicals including InChIKeys and spectral information, provided by N. Alygizakis and J. Slobodnik, EI. Dataset DOI:10.5281/zenodo.2653020
  • HBM4EU CECscreen is a suspect screening list for Chemicals of Emerging Concern (CECs) plus metadata and predicted Phase 1 metabolites; this list contains the CECs only. CECScreen is part of the HBM4EU project (coord. UBA) > WP16 emerging chemicals (lead INRA, JP Antignac/L Debrauwer) > Task 16.1 (lead IRAS, J Vlanderen / R Vermeulen) > Main contributor (J Meijer) > Involved Partners (M Lamoree, T Hamers, S Hutinet, A, Covaci, C Huber, M Krauss, DI Walker, EL Schymanski). Further details in Meijer et al (2021) DOI:10.1016/j.envint.2021.106511. Dataset DOI:10.5281/zenodo.3956586
  • List of chemicals on the market from the Swedish Chemicals Agency (KEMI). Provided by Stellan Fischer, KEMI including Hazard and Exposure scores. Curated by Reza Aalizadeh, University of Athens. Dataset DOI:10.5281/zenodo.2628786
  • The Metabolite Reaction Database, MetXBioDB, is a biotransformation database used to improve the knowledge- and machine learning-based systems of BioTransformer (http://biotransformer.ca/) by Djoumbou-Feunang et al (2019), DOI:10.1186/s13321-018-0324-5. Dataset DOI:10.5281/zenodo.4056560
  • A merged list of >100,000 structures from the NORMAN Network Suspect List Exchange, available from https://www.norman-network.com/nds/susdat/. Compiled by Reza Aalizadeh, University of Athens, including RTI and toxicity values, support by Nikiforos Alygizakis, EI. Hazard and Exposure values provided by Stellan Fischer, KEMI. Dataset DOI:10.5281/zenodo.2664077

14.9 EPA DSSTox Classification

Page of 4

14.10 PFAS and Fluorinated Organic Compounds in PubChem

  • Exact mass range 1-250
    Cases where the chemical structure exact mass is in the range of 1-250 Daltons
  • This node contains the Organofluorine Compound content from the ChEBI Ontology, which defines an organofluorine compound as a compound containing at least one carbon-fluorine bond

14.11 MolGenie Organic Chemistry Ontology

  • chiral compounds
    Compounds that cannot be superposed on its mirror image by any combination of rotations, translations, and some conformational changes.
  • monocarboxylic acids
  • biphenyls
  • drug like compounds
    Using a Fragment Based Druglikeness from OpenChemLib > -1
  • benzenes
Page of 4

14.12 Open Targets Classification

  • A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.
  • A loss of global cognitive ability of sufficient amount to interfere with normal social or occupational function. Dementia represents a loss of previously present cognitive abilities, generally in adults, and can affect memory, thinking, language, judgment, and behavior.
  • A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.

15 Information Sources

  1. CAS Common Chemistry
    LICENSE
    The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.
    https://creativecommons.org/licenses/by-nc/4.0/
  2. ChemIDplus
    ChemIDplus Chemical Information Classification
    https://pubchem.ncbi.nlm.nih.gov/source/chemidplus
  3. DrugBank
    LICENSE
    Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)
    https://www.drugbank.ca/legal/terms_of_use
  4. EPA DSSTox
    CompTox Chemicals Dashboard Chemical Lists
    https://comptox.epa.gov/dashboard/chemical-lists/
  5. European Chemicals Agency (ECHA)
    LICENSE
    Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.
    https://echa.europa.eu/web/guest/legal-notice
    (R)-2-fluoro-α-methyl[1,1'-biphenyl]-4-acetic acid
    https://chem.echa.europa.eu/100.052.041
    (R)-2-fluoro-α-methyl[1,1'-biphenyl]-4-acetic acid (EC: 257-264-7)
    https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/92990
  6. FDA Global Substance Registration System (GSRS)
    LICENSE
    Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
    https://www.fda.gov/about-fda/about-website/website-policies#linking
  7. ChEBI
  8. NCI Thesaurus (NCIt)
    LICENSE
    Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.
    https://www.cancer.gov/policies/copyright-reuse
  9. ChEMBL
    LICENSE
    Access to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).
    http://www.ebi.ac.uk/Information/termsofuse.html
  10. Open Targets
    LICENSE
    Datasets generated by the Open Targets Platform are freely available for download.
    https://platform-docs.opentargets.org/licence
    Disease Classification
    https://www.opentargets.org/
  11. ClinicalTrials.gov
    LICENSE
    The ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
  12. Drug Gene Interaction database (DGIdb)
    LICENSE
    The data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.
    http://www.dgidb.org/downloads
  13. Therapeutic Target Database (TTD)
  14. DTP/NCI
    LICENSE
    Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.
    https://www.cancer.gov/policies/copyright-reuse
  15. EU Clinical Trials Register
  16. Japan Chemical Substance Dictionary (Nikkaji)
  17. KEGG
    LICENSE
    Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license
    https://www.kegg.jp/kegg/legal.html
    Target-based classification of drugs
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
  18. MassBank of North America (MoNA)
    LICENSE
    The content of the MoNA database is licensed under CC BY 4.0.
    https://mona.fiehnlab.ucdavis.edu/documentation/license
  19. Metabolomics Workbench
  20. NIAID ChemDB
    LICENSE
    The NIAID ChemDB information received cannot be sold and is only to be used for research purposes.
  21. NORMAN Suspect List Exchange
    LICENSE
    Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0
    https://creativecommons.org/licenses/by/4.0/
    Flurbiprofen | (-)-flurbiprofen
    NORMAN Suspect List Exchange Classification
    https://www.norman-network.com/nds/SLE/
  22. Protein Data Bank in Europe (PDBe)
  23. RCSB Protein Data Bank (RCSB PDB)
    LICENSE
    Data files contained in the PDB archive (ftp://ftp.wwpdb.org) are free of all copyright restrictions and made fully and freely available for both non-commercial and commercial use. Users of the data should attribute the original authors of that structural data.
    https://www.rcsb.org/pages/policies
  24. Springer Nature
  25. Thieme Chemistry
    LICENSE
    The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.
    https://creativecommons.org/licenses/by-nc-nd/4.0/
  26. Wikidata
  27. Wikipedia
  28. Medical Subject Headings (MeSH)
    LICENSE
    Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.
    https://www.nlm.nih.gov/copyright.html
    Anti-Inflammatory Agents, Non-Steroidal
    https://id.nlm.nih.gov/mesh/M0001335.html
    Gamma Secretase Inhibitors and Modulators
    https://id.nlm.nih.gov/mesh/M000747845.html
  29. PubChem
  30. GHS Classification (UNECE)
    GHS Classification
    https://unece.org/about-ghs
  31. MolGenie
    MolGenie Organic Chemistry Ontology
    https://github.com/MolGenie/ontology/
  32. PATENTSCOPE (WIPO)
  33. NCBI
CONTENTS